ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gout and uric acid"

  • Abstract Number: 1285 • 2018 ACR/ARHP Annual Meeting

    Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study

    Min Kyung Chung1, Hyeran Hyun2, Ji Young Hwang2 and Jisoo Lee1, 1Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South), 2Department of Radiology, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South)

    Background/Purpose: Dual-energy computed tomography (DECT) allows sensitive and quantative detection of monosodium urate (MSU) crystals in patients with gout. Although its usefulness in diagnosing gout…
  • Abstract Number: 1980 • 2018 ACR/ARHP Annual Meeting

    Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility

    Hirotaka Matsuo1, Toshihide Higashino1, Tappei Takada2, Hirofumi Nakaoka3, Yu Toyoda4, Blanka Stiburkova5, Hiroshi Nakashima6, Seiko Shimizu1, Makoto Kawaguchi7, Akiyoshi Nakayama8, Yuka Aoki1, Misaki Ishino1, Yusuke Kawamura1, Kenji Wakai9, Rieko Okada10, Tatsuo Hosoya11, Kimiyoshi Ichida12, Hiroshi Ooyama13, Hiroshi Suzuki2, Ituro Inoue3, Tanya J. Major14, Tony R. Merriman14 and Nariyoshi Shinomiya1, 1Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, 2Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 3Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, 4Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine,, The University of Tokyo, Tokyo, Japan, 5Department of Pediatrics and Adolescent Medicine, Charles University and General University Hospital in Prague, First Faculty of Medicine, Prague, Czech Republic, 6Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Japan, 7National Defense Medical College, Tokorozawa, Japan, 8Dept Integrative Physiol, National Defense Medical College, Tokorozawa, Japan, 9Nagoya University Graduate School of Medicine, Nagoya, Japan, 10Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, 11Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, 12Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, 13Ryougoku East Gate Clinic, Tokyo, Japan, 14University of Otago, Dunedin, New Zealand

    Background/Purpose: We have reported that ABCG2 has an important role in both renal and intestinal urate excretion and these common variants as rs72552713 (Q126X) and…
  • Abstract Number: 2205 • 2018 ACR/ARHP Annual Meeting

    Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography

    Rehan Azeem1, Earl Sands1, Lloyd Johnston2, Wesley DeHaan Ph.D.2, Alan J. Kivitz3, Takashi Kei Kishimoto2, Justin Park1 and Savvas Nicolaou4, 1Selecta Biosciences, Inc, Watertown, MA, 2Selecta Biosciences, Watertown, MA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Radiology, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose:  Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid resolution of tophi. However, uricases are limited by induction of anti-drug…
  • Abstract Number: 2238 • 2018 ACR/ARHP Annual Meeting

    Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription

    Megan Leask1, Tony R. Merriman1, Amy Dowdle1, Hamish Salvesen1, Ruth Topless1, Tayaza Fadason2, Wenhua Wei1, William Schierding2, Justin O'Sullivan2 and Julia Horsfield1, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand

    Background/Purpose: Genome-wide association studies (GWAS) have revealed that the large majority of disease-associated single nucleotide polymorphisms (SNPs) are located in the non-coding regions of the…
  • Abstract Number: 2253 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study

    Na Lu1, Chio Yokose2, Hui Xie1,3, Gloria Li1, Sharan K. Rai4,5, Seoyoung C. Kim6 and Hyon K. Choi2, 1Arthritis Research Canada, Richmond, BC, Canada, 2Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, 3Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, 4Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 5Graduate School of Arts and Sciences, Harvard University, Cambridge, MA, 6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: A recent US Medicaid study found that in addition to certain races (Asians and Blacks), older age, female sex, chronic kidney disease (CKD), and…
  • Abstract Number: 1128 • 2018 ACR/ARHP Annual Meeting

    Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout

    In Ah Choi1, Hoyeon Jang2 and Gil-Won Kang2, 1Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of (South), 2Department of Health Informatics and Management, College of Medicine, Chungbuk National University, Cheongju, Korea, Republic of (South)

    Background/Purpose: Gout results from an increased body pool of urate that occurs with hyperuricemia. Although urate-lowering therapy (ULT) is beneficial to prevent gout attack, current…
  • Abstract Number: 1130 • 2018 ACR/ARHP Annual Meeting

    Chronic Risk Factors for Recurrent Gout Flares Among Established Gout Patients: A Prospective Cohort Analysis

    Yuqing Zhang1, Jie Wei2, Chio Yokose2, Sharan K. Rai3,4 and Hyon K. Choi2, 1Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 4Graduate School of Arts and Sciences, Harvard University, Cambridge, MA

    Background/Purpose: Understanding the risk factors for recurrent flares among established gout patients is directly relevant to clinical care; however, relevant data are scarce. A previous…
  • Abstract Number: 1284 • 2018 ACR/ARHP Annual Meeting

    Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout

    Kenneth Saag1, Mitchell Feinman2, Herbert S. B. Baraf3, Roy Fleischmann4, Arthur Kavanaugh5 and Peter E. Lipsky6, 1Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2ACME Research, LLC, Orangeburg, SC, 3Arthritis and Rheumatism Associates, Wheaton, MD, 4Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 5University of California, San Diego, School of Medicine, La Jolla, CA, 6AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite an initial…
  • Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting

    Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis

    Mary Wallace1, Rebecca Roberts2, Payal Nanavati3, Jeffrey N Miner3, Nicola Dalbeth4, Ruth Topless5, Tony R. Merriman6 and Lisa K. Stamp7, 1Surgical Sciences, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Ardea Biosciences, San Diego, CA, 4University of Auckland, Auckland, New Zealand, 5Department of Biochemistry, University of Otago, Dunedin, New Zealand, 6Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 7University of Otago, Christchurch, New Zealand

    Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
  • Abstract Number: 1110 • 2017 ACR/ARHP Annual Meeting

    Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack

    Jung Sun Lee1, Seokchan Hong2, Oh Chan Kwon2, Byeongzu Ghang2, Wook Jang Seo3, Doo-Ho Lim4, Yong-Gil Kim2, Chang Keun Lee2 and Bin Yoo2, 1Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 3Seoul Veterans Hospital, Seoul, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)

    Background/Purpose: To investigate the clinical features and risk of gout recurrence in patients with normouricemia during an acute attack Methods: This study was conducted in…
  • Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting

    Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout

    Ying-Chou Chen Sr.1, Shih-Chueh Chen2, Chung-Tei Chou3, Carl Brown4, Jing-Yi Lee4, Wei-Shu Lu5 and Chang Youh Tsai6, 1Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, 2Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, 3Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, 5TWi Biotechnology, Inc., Taipei, Taiwan, 6Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…
  • Abstract Number: 1123 • 2017 ACR/ARHP Annual Meeting

    Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout

    Sang Tae Choi1, Seong-Jin Moon2 and Eun-Jin Kang3, 1Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), 2Internal Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea, Republic of (South), 3Internal Medicine, Busan Medical Center, Busan, Korea, Republic of (South)

    Background/Purpose: Gout is a chronic inflammatory disease resulted from hyperuricemia. The measurement of 24-hour urinary uric acid excretion is frequently used to evaluate disease status…
  • Abstract Number: 1141 • 2017 ACR/ARHP Annual Meeting

    Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate

    Kenneth Saag1, Mitchell Feinman2, Alan J. Kivitz3, Herbert S. B. Baraf4, Roy Fleischmann5, Arthur Kavanaugh6 and Peter E. Lipsky7, 1Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2ACME Research, LLC, Orangeburg, SC, 3Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 4Center for Rheumatology and Bone Research, Wheaton, MD, 5Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, 6Medicine, University of California, San Diego, La Jolla, CA, 7AMPEL BioSolutions, LLC, Charlottesville, VA

    Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite initial reduction…
  • Abstract Number: 1145 • 2017 ACR/ARHP Annual Meeting

    Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals

    Kah Mun Cheong1, Archana Vasudevan2, Melonie Sriranganathan2, Elena Lee1, Serene Yeow1 and Prista Ramskay1, 1Department of Pharmacy, Changi General Hospital, Singapore, Singapore, Singapore, 2Department of Medicine, Changi General Hospital, Singapore, Singapore, Singapore

    Background/Purpose: The concept of a multidisciplinary gout clinic is relatively new in Singapore. Changi General Hospital launched such a clinic in 2014 to provide treat-to-target…
  • Abstract Number: 2058 • 2017 ACR/ARHP Annual Meeting

    A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound

    Percy Balderia and Elizabeth R. Wahl, Rheumatology, University of Washington School of Medicine, Seattle, WA

    Background/Purpose: American College of Rheumatology (ACR) guidelines recommend use of either allopurinol or febuxostat as first-line approaches to urate lowering therapy in gout. Prior studies…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology